Research on psoriasis pathogenesis has largely increased knowledge on skin biology in
general. In the past 15 years, breakthroughs in the understanding of the pathogenesis of …

Objectives We sought to evaluate the association between obesity and response to anti-
tumor necrosis factor-α (TNF) agents, through a systematic review and meta-analysis …

Background There is an unmet need for a treatment for psoriasis that results in complete
skin clearance with a reliably quick response. Bimekizumab is a monoclonal IgG1 antibody …

Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17F in addition to IL-17A. This study investigated the efficacy and safety of bimekizumab …

Importance Drug survival of biologic therapies for psoriasis is a proxy for longer-term
treatment effectiveness and safety. Patient factors that are associated with the survival of …

Background Real‐life data on newer biological and biosimilar agents for moderate‐to‐
severe psoriasis are lacking. Objectives To examine safety, efficacy and time to …

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 | British
Journal of Dermatology | Oxford Academic Skip to Main Content Advertisement intended for …

Biological therapy became available for psoriasis with the introduction of alefacept at the
beginning of this century. Up to then, systemic treatment options comprised small molecule …

Introduction New generation biologics, including interleukin (IL)-17 and IL-23 inhibitors,
have delivered higher rates of skin clearance than older treatments in head-to-head studies …

Background Drug survival is a marker for treatment sustainability in chronic diseases such
as psoriasis. Objective The aim of these analyses was to assess survival of biologic …